Colorectal cancer
2L+ MSI-H/d-MMR metastatic/recurrent CRC*,1
Colorectal cancer
2L+ MSI-H/d-MMR metastatic/recurrent CRC*,1
*Nivolumab in combination with ipilimumab is only approved for MSI-H/d-MMR CRC that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan regimen.
2L+, second-line or later; CRC, colorectal cancer; d-MMR, mismatch repair deficient; IV, intravenous; MSI-H, high microsatellite instability; QxW, every x weeks.
1. Opdivo® (nivolumab). Hong Kong Prescribing Information; Hong Kong: Bristol-Myers Squibb; 2023.